Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nippon Shinyaku
Nippon Shinyaku
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Viltepso
Viltolarsen
2020-08-12
2031
Duchenne muscular dystrophy
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Viltolarsen
duchenne muscular dystrophy
,
muscular dystrophies
Aglatimagene besadenovec
carcinoma
,
lymphoma
,
triple negative breast neoplasms
,
lung neoplasms
,
pharmacokinetics
,
healthy volunteers/patients
,
pharmacological phenomena
,
breast neoplasms
,
adenocarcinoma
,
neoplasms
,
ovarian neoplasms
,
pancreatic neoplasms
,
non-small-cell lung carcinoma
,
colorectal neoplasms
,
uterine cervical neoplasms
,
endometrial neoplasms
,
stomach neoplasms
,
urinary bladder neoplasms
,
small cell lung carcinoma
,
biliary tract neoplasms
,
bone neoplasms
,
bone diseases
,
hereditary sensory and autonomic neuropathies
,
hereditary breast and ovarian cancer syndrome
,
glioma
,
fallopian tube neoplasms
,
astrocytoma
,
head and neck neoplasms
,
dna repair-deficiency disorders
,
sarcoma
,
x-linked bulbo-spinal atrophy
,
neoplasm metastasis
,
recurrence
,
gynecomastia
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
heart failure
,
coronary disease
,
coronary artery disease
,
myocardial ischemia
,
heart diseases
,
osteoporosis
,
obesity
,
hepatocellular carcinoma
,
liver neoplasms
Alfacalcidol
ulcerative colitis
ILGINATINIB
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use